Results 111 to 120 of about 31,308 (159)
Real-World Outcomes of Efgartigimod in Adult Myasthenia Gravis. [PDF]
CureusKrall T, Byrne S, Kelbert J, Chrisman C.
europepmc +1 more source
Chimeric Antigen Receptor T-Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions. [PDF]
Muscle NerveHegelmaier T +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Seminars in Neurology, 1990
The treatment of patients with myasthenia gravis should be individualized according to the extent (ocular versus generalized) and severity (mild to severe) of disease, the presence or absence of concomitant disease (including but not limited to other autoimmune diseases and thymoma), and, to a lesser degree, the age of the patient. Thymectomy should be
D M, Linton, D, Philcox
openaire +4 more sources
The treatment of patients with myasthenia gravis should be individualized according to the extent (ocular versus generalized) and severity (mild to severe) of disease, the presence or absence of concomitant disease (including but not limited to other autoimmune diseases and thymoma), and, to a lesser degree, the age of the patient. Thymectomy should be
D M, Linton, D, Philcox
openaire +4 more sources
New England Journal of Medicine, 2016
Myasthenia gravis is an autoimmune disease, which leads to load-dependent weakness of voluntary skeletal muscles with recovery of function after resting. The disease is caused by autoantibodies directed against the postsynaptic nicotinic acetylcholine receptors (AChR) leading to a reduction of neuromuscular transmission.
Sabina, Miranda +2 more
openaire +8 more sources
Myasthenia gravis is an autoimmune disease, which leads to load-dependent weakness of voluntary skeletal muscles with recovery of function after resting. The disease is caused by autoantibodies directed against the postsynaptic nicotinic acetylcholine receptors (AChR) leading to a reduction of neuromuscular transmission.
Sabina, Miranda +2 more
openaire +8 more sources
Seminars in Neurology, 2015
Myasthenia gravis is an autoimmune neuromuscular disease caused by antibodies directed against the postsynaptic muscle membrane. The clinical hallmark of the disease is fluctuating and fatigable weakness that affects the ocular muscles (resulting in diplopia and ptosis), the bulbar muscles (causing dysphagia, dysarthria, and dyspnea), and extremity ...
Kelly G, Gwathmey, Ted M, Burns
openaire +3 more sources
Myasthenia gravis is an autoimmune neuromuscular disease caused by antibodies directed against the postsynaptic muscle membrane. The clinical hallmark of the disease is fluctuating and fatigable weakness that affects the ocular muscles (resulting in diplopia and ptosis), the bulbar muscles (causing dysphagia, dysarthria, and dyspnea), and extremity ...
Kelly G, Gwathmey, Ted M, Burns
openaire +3 more sources
Journal of Gerontological Nursing, 2013
<p>Myasthenia gravis (MG) is a chronic neuromuscular disorder characterized by fluctuating skeletal muscle weakness and fatigue. This rare autoimmune condition can present a diagnostic challenge for the advanced practice nurse (APN). Because of its low incidence in clinical practice and frequently unrecognized symptoms, a delay of 1 to 2 years ...
Julie A, Koch +2 more
openaire +3 more sources
<p>Myasthenia gravis (MG) is a chronic neuromuscular disorder characterized by fluctuating skeletal muscle weakness and fatigue. This rare autoimmune condition can present a diagnostic challenge for the advanced practice nurse (APN). Because of its low incidence in clinical practice and frequently unrecognized symptoms, a delay of 1 to 2 years ...
Julie A, Koch +2 more
openaire +3 more sources
Pediatric Annals, 1989
Twelve children with myasthenic symptoms were seen over a period of 6 years. The age of onset of symptoms ranged from 6 months to 9 years. On followup for a mean period of 4.25 years, (longest followup was 9 years) five children went into complete remission of symptoms after treatment with prostigmine; three children responded to prostigmine and ...
openaire +4 more sources
Twelve children with myasthenic symptoms were seen over a period of 6 years. The age of onset of symptoms ranged from 6 months to 9 years. On followup for a mean period of 4.25 years, (longest followup was 9 years) five children went into complete remission of symptoms after treatment with prostigmine; three children responded to prostigmine and ...
openaire +4 more sources